Ex vivo generation of human cytomegalovirus-specific cytotoxic T cells by peptide-pulsed dendritic cells

British Journal of Haematology

Volumn 113, Issue 1, 2001, Pages 231-239

  Kleihauer, Annette ^a   Grigoleit, Ulrich ^a   Hebart, Holger ^a   Moris, Arnaud ^a   Brossart, Peter ^a   Muhm, Alexandra ^a   Stevanovic, Stefan ^a   Rammensee, Hans Georg ^a   Sinzger, Christian ^a   Riegler, Susanne ^a   Jahn, Gerhard ^a   Kanz, Lothar ^a   Einsele, Hermann ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Adoptive immunotherapy; Allogeneic stem cell transplantation; Dendritic cells; HCMV; Peptides

Indexed keywords

ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL STIMULATION; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; PEPTIDE ANALYSIS; PRIORITY JOURNAL; SEROCONVERSION; T LYMPHOCYTE ACTIVATION;

ANTIGENS, VIRAL; CELL LINE; CYTOMEGALOVIRUS INFECTIONS; DENDRITIC CELLS; FIBROBLASTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 0035010709     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02681.x     Document Type: Article

References (36)

1. Phenotypic analysis of antigen specific T lymphocytes
2. The minimum peptide epitope from the influenza virus matrix protein. Extra-and intracellular loading of HLA-A2
3. Time-resolved fluorometric assay for natural killer activity using target cells labelled with a fluorescence enhancing ligand
4. Successful modification of cytomegalovirus disease in allogeneic marrow transplant recipients
5. Her-2/neu derived peptides are tumor-assiciated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes
6. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies
7. An empirical method for the prediction of T-cell epitopes
8. Development of a candidate HLA-A*0201 restricted peptide-based vaccine against human cytomegalovirus infection
9. PCR-monitoring after BMT to reduce the incidence of CMV disease and the duration and side effects of antiviral therapy
10. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection
11. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2-A1-binding melanoma and viral peptide antigens
12. HCMV infection of immature dendritic cells and of macrophages
13. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease
14. Lymphocyte responses after cytomegalovirus infection in bone marrow transplant recipients a one-year follow-up
15. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: Experience of European Bone Marrow Transplant Group
16. Identification of the major late human cytomegalovirus matrix protein pp. 65 as a target antigen for CD8+ virus specific cytotoxic T lymphocytes
17. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
18. Bone-marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes
19. Peptides naturally presented by MHC class I molecules
20. SYFPEITHI: Database for MHC ligands and peptide motifs
21. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease
22. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T-cell clones
23. Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus
24. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage clone-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
25. Minimal phenotype panels. A method for achieving maximum population coverage with a minimum of HLA antigens
26. The dominant phosphoprotein pp. 65 (UL83) of human cytomegalovirus is dispensable for growth in cell culture
27. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp. 65 that are conderved between eight strains of the virus
28. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors
29. The dendritic cell system and its role in immunogenicity
30. Induction of EBV-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus
31. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
32. The human cytotoxic (CTL) response to cytomegalovirus is dominated by structural protein pp. 65: Frequency, specificity, and T-cell receptor usage of pp. 65-specific CTL
33. HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines
34. Induction of primary human CD8 +-T lymphocyte responses in vitro using dendritic cells
35. CD14 + blood monocytes can differentiate into functionally mature CD83+ dendritic cells